口服普萘洛尔治疗婴儿血管瘤的近期和远期安全性  

Short- and long-term safety of oral propranolol in the treatment of infantile hemangioma

作　　者：于鲁 李丽[1] 马琳[1] Yu Lu;Li Li;Ma Lin(Department of Dermatology,Beijing Children′s Hospital,Capital Medical University,Beijing 100045,China)

机构地区：[1]首都医科大学附属北京儿童医院皮肤科,100045

出　　处：《中华皮肤科杂志》2019年第8期586-589,共4页Chinese Journal of Dermatology

基　　金：首都卫生发展科研专项基金(2016-2-2093);北京市属医院科研培育计划项目(PX2016014).

摘　　要：婴儿血管瘤是婴儿期最常见的肿瘤,其发病率可达4%~ 5%。血管瘤可分为高、中、低三个风险等级。目前对于高危血管瘤患者采取口服药治疗,系统治疗的一线药物为普萘洛尔(β受体阻滞剂)。应用普萘洛尔治疗血管瘤至今已有10年时间,因其有效率高及安全性好成为系统治疗的首选药物,但其远期不良反应仍需进一步研究评估。Infantile hemangioma is the most common tumor in infancy, with an incidence of 4%- 5%. According to the risk level, hemangioma is divided into 3 levels: high risk, medium risk and low risk. At present, the first-line treatment of high-risk hemangioma is oral propranolol (β-receptor blockers). It has been 10 years since infantile hemangioma was treated with propranolol for the first time, and propranolol has been the drug of first-choice in systematic treatment due to its high efficacy and good safety, but its long-term adverse effect needs further evaluation.

关 键 词：血管瘤 普萘洛尔 婴儿 远期安全性 近期安全性 

分 类 号：R732.2[医药卫生—肿瘤]